Press Releases Archives
- 12/15/10Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients with Refractory Metastatic Colorectal Cancer
-
11/17/10Jennerex Appoints Barry Sherman, M.D. to Board of Directors
-
10/21/10Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
-
09/13/10Jennerex Presents Positive Interim Data Using JX-594 and Sorafenib to Treat Liver Cancer
-
09/7/10Jennerex and Transgene Enter into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
- 08/25/10Jennerex Appoints Lara Longpre to Chief Operating Officer
-
08/19/10Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
-
06/22/10Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
-
05/20/10Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
-
05/13/10Key Clinical Data Regarding Jennerex's JX-594 to be Featured at American Society of Gene and Cell Therapy Meeting
-
04/28/10Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
-
04/19/10Positive Interim Results for JX-594 Randomized Phase 2 Liver Cancer Trial Presented at Major International Conference (EASL)
-
04/13/10Jennerex Completes Patient Enrollment in Phase 1 Trial for Intravenous Administration of JX-594
-
01/11/10Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors
-
12/23/09Jennerex Announces Presentations at Upcoming Conferences
-
11/18/09Jennerex and Lee's Pharmaceuticals Announce Partnership jor JX-594 in China
-
10/19/09Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
-
09/18/09Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
Clinical Trial Programs with Lead Product Jx-594 Funded Through 2010 -
08/11/09Jennerex Closes $5 Million First Tranche of Series C Financing
Clinical Trial Programs Funded Through 2010 -
06/11/09Jennerex Therapeutic Research Collaboration with Ottawa Hospital Research Institute Selected for $10 Million Grant from Ontario Institute for Cancer Research
-
02/10/09Nature Reviews Publishes Article about Jennerex's Multi-mechanistic Cancer Therapeutic
-
01/13/09Jennerex Appoints Samantha Miller as Vice President of Corporate Development
-
01/12/09Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
-
11/04/08Jennerex To Present at Rodman & Renshaw 10th Annual Healthcare Conference
- 10/15/08Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial with Intravenous Delivery of JX-594 Oncolytic Virus
- 09/09/08Jennerex Completes $8.3 Million Series B Financing and Appoints
Dr. Cal Stiller as Director - 07/16/08Jennerex Publishes Clinical Trial Data with Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated
Hepatitis B Virus - 06/02/08Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
- 05/21/08Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
- 11/08/07Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
- 10/23/07Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
- 10/17/06Jennerex and Green Cross Enter Agreement to Develop and Commercialize JX-594 In South Korea
